Gian Lifecare Ltd
Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories[1]
- Market Cap ₹ 18.4 Cr.
- Current Price ₹ 17.8
- High / Low ₹ 29.0 / 12.1
- Stock P/E 4.52
- Book Value ₹ 19.2
- Dividend Yield 0.00 %
- ROCE 29.2 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.93 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -0.83%
- Promoter holding is low: 32.0%
- Promoters have pledged 62.3% of their holding.
- Debtor days have increased from 94.5 to 137 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 5m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|
| 0.56 | 7.31 | 10.24 | 15.45 | 11.41 | 12.78 | 12.32 | |
| 0.36 | 5.23 | 7.14 | 9.39 | 9.37 | 6.58 | 6.52 | |
| Operating Profit | 0.20 | 2.08 | 3.10 | 6.06 | 2.04 | 6.20 | 5.80 |
| OPM % | 35.71% | 28.45% | 30.27% | 39.22% | 17.88% | 48.51% | 47.08% |
| -0.00 | 0.10 | 0.29 | 0.51 | 0.69 | 0.64 | 0.67 | |
| Interest | 0.04 | 0.37 | 0.35 | 0.39 | 0.45 | 0.47 | 0.43 |
| Depreciation | 0.02 | 0.26 | 0.29 | 0.33 | 0.50 | 0.46 | 0.44 |
| Profit before tax | 0.14 | 1.55 | 2.75 | 5.85 | 1.78 | 5.91 | 5.60 |
| Tax % | 21.43% | 28.39% | 26.91% | 25.30% | 29.78% | 27.24% | |
| 0.10 | 1.13 | 2.02 | 4.37 | 1.26 | 4.30 | 4.08 | |
| EPS in Rs | 1.10 | 1.96 | 4.23 | 1.22 | 4.16 | 3.96 | |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 8% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 112% |
| 3 Years: | 29% |
| TTM: | 181% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | -29% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 23% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 4.70 | 4.70 | 10.34 | 10.34 | 10.34 | 10.34 |
| Reserves | 0.10 | 2.94 | 4.96 | 3.69 | 4.97 | 9.27 | 9.53 |
| 1.36 | 1.09 | 1.00 | 2.03 | 4.57 | 4.17 | 4.00 | |
| 6.34 | 3.64 | 4.82 | 7.00 | 8.52 | 8.28 | 9.94 | |
| Total Liabilities | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 33.81 |
| 2.91 | 2.84 | 2.99 | 3.50 | 4.62 | 4.47 | 4.24 | |
| CWIP | -0.00 | -0.00 | -0.00 | 0.12 | 0.14 | 0.14 | 0.14 |
| Investments | -0.00 | -0.00 | -0.00 | 0.11 | 0.11 | 0.11 | 0.11 |
| 4.90 | 9.53 | 12.49 | 19.33 | 23.53 | 27.34 | 29.32 | |
| Total Assets | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 33.81 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 2.99 | 1.51 | 2.87 | 5.79 | 2.32 | 0.75 | |
| -2.92 | -3.96 | -1.10 | -4.23 | -0.94 | 0.33 | |
| 0.96 | 2.55 | -0.39 | 0.67 | -0.37 | -0.86 | |
| Net Cash Flow | 1.03 | 0.10 | 1.38 | 2.23 | 1.01 | 0.22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 860.36 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 |
| Inventory Days | 4,380.00 | |||||
| Days Payable | 5,266.43 | |||||
| Cash Conversion Cycle | -26.07 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 |
| Working Capital Days | -2,887.41 | -40.44 | -52.04 | -31.42 | -66.54 | -1.43 |
| ROCE % | 37.65% | 31.98% | 46.71% | 12.41% | 29.23% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended 31St December, 2024
10 Feb - Board meeting to approve Q4 financial results.
- Outcome Of Board Meeting Held On Thursday, November 14, 2024 14 Nov 2024
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, November 14, 2024
14 Nov 2024 - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year Ended 30Th September, 2024
8 Nov 2024 - Board meeting to approve Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Oct 2024 - Certificate under reg 74(5) of M/s. Gian Life Care Ltd
Annual reports
Concalls
-
Nov 2021TranscriptNotesPPT
Business Overview:[1]
GLL provides diagnostic and healthcare testing services across Kanpur and nearby cities. It offers patient diagnosis, prevention, and wellness services to individuals and healthcare providers. The company is expanding its network with new diagnostic labs nationwide. In addition to its major lab in Kanpur, its Lucknow lab became fully operational in FY23.